Perioperative clinical and economic outcomes associated with replacing first-generation high molecular weight hydroxyethyl starch (Hextend®) with low molecular weight hydroxyethyl starch (Voluven®) at a large medical center

BACKGROUND: Several plasma volume expander alternatives exist to enhance intravascular volume status in patients undergoing surgery. The optimal intravascular volume expander in the perioperative setting is currently unknown. Low molecular weight hetastarch, Voluven® (130/0.4), may have a better saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartz, Raquel R, White, William D, Gan, Tong J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349603/
https://www.ncbi.nlm.nih.gov/pubmed/25741439
http://dx.doi.org/10.1186/s13741-015-0013-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349603/
https://www.ncbi.nlm.nih.gov/pubmed/25741439
http://dx.doi.org/10.1186/s13741-015-0013-0

Ejemplares similares